Pfizer Secures FDA Priority Review For TALZENNA Plus XTANDI In Metastatic Prostate Cancer

Source Summary

Pfizer Inc. (PFE) said the U.S. FDA has accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA (talazoparib), in combination with XTANDI (enzalutamide) for men with metastatic castration-sensitive prostate cancer (mCSPC), carrying homologous recombinant repair (HRR) gene alterations.